Avian adenovirus CELO recombinants expressing VP2 of infectious bursal disease virus induce protection against bursal disease in chickens.

Vaccine

Agence Française de Sécurité Sanitaire des Aliments, Molecular Biology Unit, Zoopôle Les Croix, B.P. 53, Ploufragan 22440, France.

Published: June 2004

AI Article Synopsis

  • Researchers developed a CELO virus vector to protect against infectious bursal disease by incorporating the VP2 antigen from IBDV under a CMV promoter.
  • The engineered CELO recombinants were non-pathogenic and, while some vaccination methods offered poor protection, subcutaneous or intradermic injections of CELOa-VP2 resulted in no clinical signs after challenge with virulent IBDV.
  • Despite achieving good humoral response and weight ratios similar to commercial vaccines, some histological lesions were observed, indicating that comprehensive protection was not fully achieved.

Article Abstract

To develop a CELO virus vector that can induce protection against infectious bursal disease, CELO viruses expressing the host-protective antigen VP2 of infectious bursal disease virus (IBDV) were constructed. In the engineered recombinants, the VP2 gene (the 441-first codons of the IBDA polyprotein) was placed under the control of the CMV promoter. Two positions in the CELO genome were chosen to insert the VP2 expression cassette. The recombinants were found apathogenic, when inoculated by different routes and even at high doses (up to 10(8) per animal). Chickens vaccinated oro-nasally with these different recombinants and challenged with very virulent IBDV were found to be poorly protected. In contrast, when inoculated with one or two (subcutaneous or intradermic) injections of CELOa-VP2, the chickens showed no clinical signs and no mortality after challenge. In the vaccinated chickens, the titers of neutralization antibody reached 7-9 values, showing that protection could be explained by the induction of a sufficient humoral response. After challenge, the weight ratio Bursa of Fabricius/body was about 2.5 per thousand, a value similar to that obtained with the commercial Bur706 vaccine. However, histological lesions in the Bursa of Fabricius were observed, showing that a complete protection was not totally achieved. Contact transmission was evidenced. Protection was also obtained when inoculation of CELOa-VP2 was carried out in ovo. Prime-boost strategies were also tested with the CELOa-VP2 vector used in association with the purified VP2 antigen, or DNA encoding VP2 or a CELO vector expressing chicken myeloid growth factor (cMGF). None of these regimens were shown to substantially increase the level of protection when compared to double CELOa-VP2 inoculations. These results indicate that CELO-based vectors are useful to safely induce a strong protective immunity against vvIBDV in chickens.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2003.10.039DOI Listing

Publication Analysis

Top Keywords

bursal disease
16
infectious bursal
12
vp2 infectious
8
disease virus
8
induce protection
8
vp2
6
protection
6
celo
5
chickens
5
avian adenovirus
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!